SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital.
Adolescent
Adult
COVID-19
/ diagnosis
COVID-19 Nucleic Acid Testing
/ statistics & numerical data
COVID-19 Serological Testing
/ statistics & numerical data
Egypt
Female
Hospitals, University
/ statistics & numerical data
Humans
Male
Mass Screening
/ statistics & numerical data
Middle Aged
Seroepidemiologic Studies
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
02
2021
accepted:
29
06
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
31
7
2021
Statut:
epublish
Résumé
Research has revealed that asymptomatic and pre-symptomatic infections are important contributors to the transmission of SARS-CoV-2 in populations. In Egypt, the true prevalence of infections is veiled due to the low number of screening tests. The aim of this study was to determine the SARS-CoV-2 PCR positivity rate as well the seroprevalence of the SARS-CoV-2 antibodies before the ultimate development of a second wave of the epidemic in Cairo, Egypt. Our study was carried out between May 5 and the end of October 2020. It included all patients requiring admission to Ain Shams University hospitals. An interview questionnaire was used to collect demographic and clinical data. Laboratory tests for all participants included RT-PCR and total antibody assay for SARS-CoV-2. A total of 4,313 subjects were enrolled in our study, with females representing 56% of the sample. Adults and middle-aged individuals represented around 60% of the study sample. The positivity rate of SARS-CoV-2 PCR was 3.84% (95% CI 3.29-4.48), and the SARS-CoV-2 antibody seroprevalence was 29.82% (95% CI: 28.16-31.51). Males showed a higher risk for getting the COVID-19 infection, while middle-age group had significantly higher antibody seroprevalence rates. SARS-CoV-2 infection imposes a high burden on the community as detected by high seroprevalence rates.
Sections du résumé
BACKGROUND
Research has revealed that asymptomatic and pre-symptomatic infections are important contributors to the transmission of SARS-CoV-2 in populations. In Egypt, the true prevalence of infections is veiled due to the low number of screening tests. The aim of this study was to determine the SARS-CoV-2 PCR positivity rate as well the seroprevalence of the SARS-CoV-2 antibodies before the ultimate development of a second wave of the epidemic in Cairo, Egypt.
METHODS
Our study was carried out between May 5 and the end of October 2020. It included all patients requiring admission to Ain Shams University hospitals. An interview questionnaire was used to collect demographic and clinical data. Laboratory tests for all participants included RT-PCR and total antibody assay for SARS-CoV-2.
RESULTS
A total of 4,313 subjects were enrolled in our study, with females representing 56% of the sample. Adults and middle-aged individuals represented around 60% of the study sample. The positivity rate of SARS-CoV-2 PCR was 3.84% (95% CI 3.29-4.48), and the SARS-CoV-2 antibody seroprevalence was 29.82% (95% CI: 28.16-31.51). Males showed a higher risk for getting the COVID-19 infection, while middle-age group had significantly higher antibody seroprevalence rates.
CONCLUSION
SARS-CoV-2 infection imposes a high burden on the community as detected by high seroprevalence rates.
Identifiants
pubmed: 34265021
doi: 10.1371/journal.pone.0254581
pii: PONE-D-21-06534
pmc: PMC8282003
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0254581Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Endocrinol Invest. 2020 Jun;43(6):867-869
pubmed: 32222956
Emerg Infect Dis. 2020 Aug;26(8):1935-1937
pubmed: 32392125
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Am J Hypertens. 2020 Apr 29;33(5):373-374
pubmed: 32251498
J Microbiol Immunol Infect. 2021 Feb;54(1):97-100
pubmed: 32684340
J Econom. 2021 Jan;220(1):106-129
pubmed: 32921876
J Med Virol. 2021 Jan;93(1):151-152
pubmed: 32603509
Clin Infect Dis. 2021 Nov 2;73(9):e2908-e2917
pubmed: 32945845
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Aug 22;396(10250):514-515
pubmed: 32645348
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
J Microbiol Immunol Infect. 2021 Apr;54(2):164-174
pubmed: 32513617
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Infect Control Hosp Epidemiol. 2021 Sep;42(9):1158-1160
pubmed: 32843119
F1000Res. 2020 Apr 30;9:315
pubmed: 32528664
Lancet Infect Dis. 2020 Aug;20(8):894
pubmed: 32222162
Sci Immunol. 2020 Dec 7;5(54):
pubmed: 33288645
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
Crit Care. 2020 Apr 30;24(1):188
pubmed: 32354360
Clin Microbiol Infect. 2021 Apr;27(4):633.e1-633.e7
pubmed: 33253941
J Infect. 2020 Jun;80(6):656-665
pubmed: 32283155
MMWR Morb Mortal Wkly Rep. 2020 Aug 14;69(32):1100-1101
pubmed: 32790658
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
N Engl J Med. 2020 May 28;382(22):2081-2090
pubmed: 32329971
PLoS One. 2020 Dec 10;15(12):e0242958
pubmed: 33301459
PLoS Pathog. 2020 Jun 22;16(6):e1008570
pubmed: 32569293
Infection. 2015 Aug;43(4):399-403
pubmed: 25956991
PLoS One. 2020 Dec 17;15(12):e0243027
pubmed: 33332356
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Lancet Infect Dis. 2021 Apr;21(4):473-481
pubmed: 33338441
Am J Physiol Endocrinol Metab. 2020 Sep 1;319(3):E562-E567
pubmed: 32726128
Clin Infect Dis. 2021 Nov 2;73(9):e2853-e2860
pubmed: 33011792
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Mol Metab. 2020 Sep;39:101044
pubmed: 32585364
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):303-310
pubmed: 32298981
MMWR Morb Mortal Wkly Rep. 2020 Jul 24;69(29):965-970
pubmed: 32701941
J Clin Virol. 2020 Jun;127:104378
pubmed: 32353762
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
J Ovarian Res. 2020 Nov 24;13(1):137
pubmed: 33234144
Front Public Health. 2020 Apr 29;8:152
pubmed: 32411652